CHANTAL COUGHLIN: Open Payments
NPI 1477038867 · SALEM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$845 in 11 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $522 · 2025 $845
Food & beverage: $845
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $258 |
| Gilead Sciences, Inc. | 2 | $167 |
| Madrigal Pharmaceuticals | 1 | $139 |
| Phathom Pharmaceuticals, Inc. | 1 | $118 |
| Alnylam Pharmaceuticals Inc. | 1 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Hologic Sales and Service, LLC | 1 | $25 |
Products named: CAPLYTA, REZDIFFRA, Yeztugo, VOQUEZNA, AMVUTTRA, TRINTELLIX, APTIMA.
Industry payments across MA — which companies pay providers there.
